Acute Renal Failure Clinical Trial
— BH4POfficial title:
Can bh4 Levels Predict Severity and Complications of Pre Eclampsia in Pregnant Women
Verified date | December 2023 |
Source | University Tunis El Manar |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
tetrahydrobiopterin (BH4) is degraded by several enzymes, including BH4 oxidase and peroxidases. Several factors can affect its synthesis and degradation. BH4 deficiency or depletion and genetic variations in the genes involved in BH4 metabolism have been associated with hypertension, suggesting that BH4 may play a role in the pathogenesis of hypertension. The maternity center of Tunis ( CMNT ) is a level 3 maternity center, supporting over 12 000 births yearly, where the caesarean section's rate is very high, close to 45% of deliveries. Early detection of these patients can help control maternal and neonatal safety outcomes. we can avoid complications such as severe preeclampsia, HELLP syndrom and eclampsia for the mother, and preterm delievery and fetal growth restriction for the new born. in the literature, studies have reported a decrease in BH4 levels in pregnant women compared to non-pregnant women and others showed that its deficiency or depletion has been associated with hypertension. Moreover, tetrahydrobiopterin administration has been studied as a potential treatment for preeclampsia but the optimal dose has not yet been determined, and further studies are needed to determine the appropriate dose, timing, and duration of BH4 supplementation in this context. Thus, BH4 blood levels as a mean of screening, could enrich our diagnostic arsenal. The purpose of our study is to compare BH4 levels between preeclamptic and normotensive women.
Status | Completed |
Enrollment | 300 |
Est. completion date | December 6, 2023 |
Est. primary completion date | July 31, 2023 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Women aged over 18 YEARS - informed consent - Pregnant - Term of pregnancy over than 24 weeks of gestation - Having a normal pregnancy ( for the control group) - Being diagnosed with preeclampsia or severe preeclampsia as defined in international guidelines (for the case group) Non- inclusion Criteria: - Women with known phenylketonuria - Any history of ( treated or not) hypertension prior to the current pregnancy - Any history of ( treated or not) diabetes or gestational diabetes during the current pregnancy - Any history of renal failure or kidney injury) in the current pregnancy - Women under long-term medications for arterial hypertension or before 24 week of the current pregnancy |
Country | Name | City | State |
---|---|---|---|
Tunisia | Tunis maternity and neonatology center, minisetry of public health | Tunis |
Lead Sponsor | Collaborator |
---|---|
University Tunis El Manar |
Tunisia,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | the association between BH4 blood level (ng/mL) and preterm delivery (before 37 weeks of pregnancy) | Secondary outcome measures will include the predectivity of preterm delivery with BH4 levels | From date of first admission until the date of foetal extraction, starting from 20 weeks of pregnancy to it's end (Maximal time frame : 22 weeks) | |
Other | the association between BH4 blood level (ng/mL) and fetal growth restriction. | Secondary outcome measures will include the association between BH4 levels and fetal growth restriction. | From date of first admission until the date of foetal extraction, starting from 20 weeks of pregnancy to it's end (Maximal time frame : 22 weeks) | |
Other | the association between BH4 blood level (ng/mL) and placenta abroptio | econdary outcome measures will include the association between BH4 levels and placenta abroptio | From date of first admission until the date of foetal extraction, starting from 20 weeks of pregnancy to it's end (Maximal time frame : 22 weeks) | |
Other | the association between BH4 blood level (ng/mL) and mortality | predectivity of maternal and foetal mortality by BH4 levels | From date of first admission until the date of foetal extraction, starting from 20 weeks of pregnancy to it's end (Maximal time frame : 22 weeks) | |
Primary | the association between BH4 blood level (ng/mL) and severity of preeclampsia (biological and clinical criteria) | The primary outcome measure will be the association between BH4 levels and the severity of preeclampsia, including maternal and fetal complications Preeclampsia is defined by : Systolic blood pressure (SBP) higher than 140 mmHg or/and diastolic blood pressure (DBP)higher than 90 mmHg whith proteinuria higher than 0.3 g/24 h
Its sevrity is defined by at least one of those criteria: SBP > 160 mmHg and/or DBP >110 mmHg proteinuria > 3g/24h creatini level > 90 µmol/ l oliguria < 500 ml /24 hours or < 25 ml/ h thrombocytopenia < 100.000/mm3 Cytolysis > two times the normal value neurosensory signs chest pain , acute lung edema, dyspnea |
From date of first admission until the date of foetal extraction, starting from 20 weeks of pregnancy to it's end (Maximal time frame : 22 weeks) | |
Secondary | the association between BH4 blood level (ng/mL) and gestational hypertension. | Secondary outcome measures will include the associationtion between BH4 levels and gestational hypertension.
gestational hypertension are defined by High Blood pressure SBP > 160 mmHg and/or DBP > 90 mmHg without proteinuria or any other preeclamptic criteria |
From date of first admission until the date of foetal extraction, starting from 20 weeks of pregnancy to it's end (Maximal time frame : 22 weeks) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01946113 -
Mineral-Homeostasis in Continuous Renal Replacement Therapy
|
N/A | |
Withdrawn |
NCT00993733 -
Assessing the Impact of Two Methods of Continuous Veno-venous Hemodiafiltration on Time Nursing Work in Intensive Care
|
N/A | |
Completed |
NCT01476995 -
Prognostic Indicators as Provided by the EPIC ClearView
|
N/A | |
Terminated |
NCT00978354 -
Furosemide in Early Acute Kidney Injury
|
Phase 2/Phase 3 | |
Completed |
NCT00120263 -
Trial of Plasma Exchange for Acute Renal Failure at the Onset of Myeloma
|
N/A | |
Completed |
NCT04799600 -
The Effect of the Severity of COVID-19 Disease on the Incidence of Acute Renal Failure in ICU
|
||
Recruiting |
NCT04334707 -
Kidney Precision Medicine Project
|
||
Completed |
NCT02858531 -
Predictive Tracking of Patient Flow in the Emergency Services During the Virus Winter Epidemics
|
||
Recruiting |
NCT05282732 -
Retrospective Analysis of Performance and Treatment Data Collected for Genius SleddFlux Filter, Ultraflux AV 600 S Filter & Genius 90 Concentrates in Haemodialysis Patients
|
||
Completed |
NCT01467466 -
Prevention of Serious Adverse Events Following Angiography
|
Phase 3 | |
Completed |
NCT01979042 -
Urinary Markers for Unilateral Kidney Obstruction
|
N/A | |
Completed |
NCT01280617 -
Low Dose Thymoglobin in Renal Transplant Patients
|
N/A | |
Completed |
NCT00780351 -
Dosing Vancomycin in Patients on Sustained Low Efficiency Daily Hemodiafiltration (SLEDD-f)
|
N/A | |
Completed |
NCT00971971 -
Prevention of Intradialytic Hypotension in Acute Kidney Injury Patients
|
N/A | |
Completed |
NCT00076219 -
Acute Renal Failure Trial Network (ATN) Study
|
Phase 3 | |
Recruiting |
NCT04599569 -
Influence of Renal Replacement TherApy on Indirect Calorimetry
|
||
Completed |
NCT03727204 -
Acute Kidney Injury After Cardiac Surgery: Novel Ultrasound Techniques for Prediction of Acute Kidney Injury
|
||
Completed |
NCT06005896 -
A Clinical Model for Dialysis Discontinuation in AKI
|
||
Completed |
NCT03627884 -
Outcomes of the Use of Sodium Bicarbonate (8.4%) Solution as a Catheter Lock Solution to Prevent Hemodialysis Catheter Loss Due to Lumen Clot Formation
|
Phase 4 | |
Completed |
NCT03004950 -
Biomarker Effectiveness Analysis in Contrast Nephropathy (BEACON)
|